Viking Therapeutics Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial Results

Viking Therapeutics, a clinical-stage biopharma company, is nearing a breakthrough in its obesity drug VK2735 with Phase 3 trials. The dual GLP-1/GIP receptor agonist has shown significant weight loss and safety in Phase 1 and 2 trials. The company is also expanding its pipeline with a novel amylin agonist program and advancing VK2809 for NASH. With $808 million in cash, Viking is well-positioned to fund upcoming milestones.

Viking Therapeutics, Inc. (NASDAQ: VKTX) has made significant progress in its obesity treatment pipeline with the initiation of Phase 3 trials for its dual GLP-1/GIP receptor agonist, VK2735 [1]. The company's lead candidate, VK2735, has shown promising results in Phase 1 and 2 trials, demonstrating significant weight loss and safety [2]. The launch of the Phase 3 trials signals confidence in VK2735’s potential and could catalyze interest and investment in VKTX, especially given its clinical potential in a large market [1].

The Phase 3 results, expected in the future, may significantly influence VKTX’s valuation. Historically, successful phase transitions can lead to increased stock prices [1]. Viking Therapeutics is also expanding its pipeline with a novel amylin agonist program aimed at metabolic disorders, expecting to file an IND by Q4 2025 [2]. Additionally, VK2809, a thyroid hormone receptor beta agonist for NASH, has shown positive Phase 2b results.

With $808 million in cash (as of June 2025), Viking Therapeutics is well-positioned to fund upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are key near-term catalysts for the company [2].

References:
[1] https://stocknews.ai/ai-news/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1-gip-agonist-vk2735/685bddd3c7f2a98920371101
[2] https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-nears-153723414.html